Human papillomavirus vaccine TA-CIN - Cancer Research Technology
Alternative Names: TA-CIN; Therapeutic HPV vaccine - Cancer Research TechnologyLatest Information Update: 26 Nov 2021
At a glance
- Originator Xenova Group
- Class Cancer vaccines; Papillomavirus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Human papillomavirus infections
Highest Development Phases
- Phase II Vulvar intraepithelial neoplasia
- No development reported Cervical dysplasia
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Cervical-dysplasia in Netherlands (Parenteral, Injection)
- 09 Oct 2017 Sidney Kimmel Comprehensive Cancer Center plans a phase I trial for Cervical cancer (Adjuvant therapy) in USA (NCT02405221)
- 29 Jul 2015 TA-CIN is still in active development with non-industrial organisations